2019 was an average year for medtech M&A. 2020, not so much.
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
The FDA is loosening its rules on the authorisation of diagnostic tests for the new coronavirus, but it is still some way behind Europe.
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.
The Dutch group is ripe for a takeover, and while Thermo Fisher has to be the likeliest candidate for acquirer there are a number of potentially interested parties.